Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Hepatic Surgery(Electronic Edition) ›› 2021, Vol. 10 ›› Issue (06): 618-621. doi: 10.3877/cma.j.issn.2095-3232.2021.06.018

• Clinical Researches • Previous Articles     Next Articles

Diagnosis and treatments of primary hepatic leiomyosarcoma

Yang Wu1, Runchen Miao1, Xing Zhang1, Yuelang Zhang2, Xiaohua Ma1, Chang Liu1,()   

  1. 1. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
    2. Department of Imaging, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
  • Received:2021-08-24 Online:2021-09-23 Published:2022-01-26
  • Contact: Chang Liu

Abstract:

Objective

To investigate the diagnosis and treatments of primary hepatic leiomyosarcoma (PHL).

Methods

Clinical data of 1 patient with PHL who was diagnosed and treated in the First Affiliated Hospital of Xi'an Jiaotong University in October 2017 were analyzed retrospectively. The female patient, aged 49 years, was admitted to our hospital due to "space-occupying lesions of the liver detected by ultrasound examination". A hypoechoic region in the caudate lobe of liver was found by ultrasound examination. Multiple nodule-like and lumpy low-density shadows in the right lobe and caudate lobe were observed by abdominal CT scan. The diagnosis of PHL was confirmed by liver biopsy and immunohistochemical staining. TACE combined with chemotherapy was adopted.

Results

The patient received TACE on December 14, 2017, and was given with 6 cycles of adjuvant chemotherapy (gemcitabine+docetaxel) after TACE. The lesion was found slightly enlarged in the reexamination on April 16, 2019 and the chemotherapy regimen was modified to gemcitabine + albumin-bound paclitaxel for 3 cycles. On May 20, 2020, the reexamination found that the lesion was obviously enlarged. After the secondary TACE, the patient recovered well. As of July 1, 2020, the patient had lived a high quality of life, and no tumor recurrence was found during postoperative follow-up. Clinical data of 15 adult patients with PHL were retrieved from PubMed database between 2000 and 2020. 6 cases were male and 9 female, aged from 25 to 77 years, with a median age of 54 years. The primary symptoms were mainly abdominal pain and discomfort, and the tumors were mainly located in the right lobe. No specific manifestations was observed in laboratory and imaging examination. Pathological examination showed that spindle-shaped tissue cells were arranged in bundles. Immunohistochemical staining found positive results for SMA, desmin and vimentin, whereas negative results for S-100 and cytokeratin in the tissue cells. Surgical resection was performed in 9 cases, chemotherapy in 2, including 1 of surgical resection combined with chemotherapy, liver transplantation in 1, TACE in 2 and conservative treatments in 2, respectively. During 3-82 month follow-up, 2 cases were lost to follow-up, 6 cases died and 7 survived.

Conclusions

PHL is a rare disease. Pathological examination is the only effective approach to confirm the diagnosis. Surgical resection can achieve relatively better clinical efficacy.

Key words: Liver neoplasms, Leiomyosarcoma, Diagnosis, Treatment

京ICP 备07035254号-20
Copyright © Chinese Journal of Hepatic Surgery(Electronic Edition), All Rights Reserved.
Tel: 020-85252582 85252369 E-mail: chinaliver@126.com
Powered by Beijing Magtech Co. Ltd